REQUEST A DEMO
Total
USD $0.00
Search more companies

Optimapharm Lithuania UAB (Lithuania)

Main Activities: Research and Development in Nanotechnology | Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Full name: Optimapharm Lithuania UAB Profile Updated: January 01, 2025
Buy our report for this company USD 29.95 Most recent financial data: 2024 Available in: English & Russian Download a sample report

Optimapharm Lithuania UAB is based in Lithuania, with the head office in Kaunas. The company operates in the Research and Development in Nanotechnology sector. Optimapharm Lithuania UAB was incorporated on May 14, 2015. It currently has a total number of 15 (2025) employees. The company’s latest financial report indicates a net sales revenue drop of 6.73% in 2024. Optimapharm Lithuania UAB’s net profit margin increased by 1.69% in 2024.

Headquarters
R. Kalantos g. 161
Kaunas; Kaunas County; Postal Code: LT-52315

Contact Details: Purchase the Optimapharm Lithuania UAB report to view the information.

Basic Information
Total Employees:
Purchase the Optimapharm Lithuania UAB report to view the information.
Registered Capital:
Purchase the Optimapharm Lithuania UAB report to view the information.
Financial Auditors:
Purchase the Optimapharm Lithuania UAB report to view the information.
Incorporation Date:
May 14, 2015
Key Executives
Purchase this report to view the information.
Member of the Management Board
Company Performance
Financial values in the chart are available after Optimapharm Lithuania UAB report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency EUR. Absolute financial data is included in the purchased report.
Net sales revenue
-6.73%
Total operating revenue
-6.73%
Net Profit (Loss) for the Period
37.01%
Total Equity
19.03%
Net Profit Margin
1.69%
Return on Equity (ROE)
2.1%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?